GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Reports Q2 FY27 Net Profit of Rs. 3,913.47 Lakhs

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 04 Nov 2026, 01:39 PM IST  ·  BSE ID: 2900b5ac-890f-4fc1-892d-b8459aea5eed
View Original BSE Filing (PDF)
💡
In Simple Terms
SMS Pharmaceuticals saw its quarterly profit jump by 55.65% and appointed a new company secretary.
🤖 AI Summary
  • SMS Pharmaceuticals reported Q2 FY27 standalone net profit of Rs. 3,913.47 Lakhs, a 55.65% increase.
  • Revenue from operations for Q2 FY27 reached Rs. 31,607.41 Lakhs, up 30.38% from Q2 FY26.
  • For H1 FY27, net profit was Rs. 6,026.73 Lakhs on revenue of Rs. 52,303.90 Lakhs.
  • Mr. Thirumalesh Tumma resigned as Company Secretary, effective November 4, 2026.
  • Mr. Manohar Mollama was appointed as the new Company Secretary and Compliance Officer from November 5, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
Rs. 31,607.41 Lakhs
30.38%
Net Profit After Tax (Q2 FY27)
Rs. 3,913.47 Lakhs
55.65%
Revenue from Operations (H1 FY27)
Rs. 52,303.90 Lakhs
19.29%
Net Profit After Tax (H1 FY27)
Rs. 6,026.73 Lakhs
39.04%
Basic/Diluted EPS (Q2 FY27)
Rs. 4.18
48.23%
🏢 How This Affects the Company
📈
Business Impact
The increase in revenue from operations to Rs. 31,607.41 Lakhs for Q2 FY27 indicates growth in the company's core Active Pharmaceutical Ingredients manufacturing segment.
💰
Financial Impact
Net profit after tax grew by 55.65% YoY to Rs. 3,913.47 Lakhs for Q2 FY27, and by 39.04% for H1 FY27, improving overall profitability.
⚙️
Operational Impact
The change in Company Secretary and Compliance Officer is a routine management transition and does not immediately impact core operational processes.
⚠️
Risk Impact
The immediate replacement of the Company Secretary ensures continuity in compliance functions, mitigating potential governance risks.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with the significant 55.65% YoY rise in net profit for Q2 FY27 reflecting improved earnings.
🔍
Management Signal
The swift appointment of a new Company Secretary, Mr. Manohar Mollama, indicates management's focus on maintaining corporate governance and compliance continuity.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor if revenue growth sustains above Q2 levels.
Future management disclosures — observe continuity of compliance practices under new CS.
Capital expenditure details — check for progress on property, plant and equipment additions.
LOW RISK The filing reports strong financial performance and a smooth management transition.
💡 Investor Takeaway
SMS Pharmaceuticals reported Q2 FY27 standalone net profit of Rs. 3,913.47 Lakhs, a 55.65% increase from Rs. 2,514.30 Lakhs in Q2 FY26. Revenue from operations increased by 30.38% to Rs. 31,607.41 Lakhs. The Board approved the resignation of Mr. Thirumalesh Tumma and appointed Mr. Manohar Mollama as Company Secretary.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 revenue from operations increased 30.38% YoY to Rs. 31,607.41 Lakhs, indicating strong top-line growth.
  • Net Profit After Tax for Q2 FY27 grew 55.65% YoY to Rs. 3,913.47 Lakhs, demonstrating enhanced profitability.

⚠️ Concerns

  • Cost of Materials Consumed for H1 FY27 increased to Rs. 30,496.39 Lakhs, up 21.57% YoY, impacting cost efficiency.
  • Cash and Cash Equivalents decreased to Rs. 3,599.40 Lakhs as of 30 September 2026, from Rs. 4,578.15 Lakhs as of 31 March 2026.
📅 Company Track Record
SMS Pharmaceuticals Ltd reported Q1 FY27 revenue up 6% YoY to ₹207.0 Cr, with PAT up 8% YoY, as per its August 1, 2026 press release. The current Q2 FY27 results show accelerated growth compared to Q1 FY27.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was SMS Pharmaceuticals' net profit for Q2 FY27?
SMS Pharmaceuticals reported a standalone net profit after tax of Rs. 3,913.47 Lakhs for the quarter ended 30th September 2026 (Q2 FY27).
How did SMS Pharmaceuticals' revenue from operations perform in Q2 FY27?
Revenue from operations for SMS Pharmaceuticals reached Rs. 31,607.41 Lakhs in Q2 FY27, showing a 30.38% increase compared to Q2 FY26.
Who is the new Company Secretary for SMS Pharmaceuticals?
Mr. Manohar Mollama (ICSI M.No. F11904) has been appointed as the new Company Secretary and Compliance Officer for SMS Pharmaceuticals, effective from November 5, 2026.
What were the half-year (H1 FY27) financial results for SMS Pharmaceuticals?
For the half-year ended 30th September 2026 (H1 FY27), SMS Pharmaceuticals reported revenue from operations of Rs. 52,303.90 Lakhs and a net profit after tax of Rs. 6,026.73 Lakhs.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.